On September 1, 2021 OncoOne is pleased to welcome Dr. Sara Sajko to our team as a Scientist. Sara will be instrumental in supporting our Biotechnology Group, particularly in antibody design and characterization efforts.

On August 2, 2021 OncoOne is delighted to welcome Dr. Christine Landlinger-Schubert as our new Director of Preclinical Development & Project Lead for Inflammation. In her role, Christine will oversee and manage non-clinical studies for our innovative new biotherapeutics.

On May 15, 2021, in Vienna, Austria, OncoOne proudly announces the completion of its first academic thesis. Our team member, Gregor Rossmüller, has successfully conducted and finalized his master’s thesis titled “Purification and characterization of anti-CD3/anti-oxMIF bispecific antibodies or antibody-like molecules for the treatment of

On April 1, 2021, OncoOne introduced Friedmund Bachmann as our new Director of CMC Biologics, joining our team in Vienna, Austria. Friedmund will provide valuable support in manufacturing, analytics, and quality control efforts.

Meet our CEO, Randolf Kerschbaumer and CSO, Michael Thiele at the digital BIO-Europe Spring to learn more about OncoOne’s mission to develop novel, anti-cancer therapies for the treatment of solid tumors.

On March 1, 2021, OncoOne warmly welcomed Alejandro Puchol Tarazona, PhD to our Biotechnology Group as our new Scientist. Alejandro will contribute his expertise to support protein engineering activities and protein production.

On June 1, 2020, OncoOne warmly welcomed Maria Reitzinger to our team as our new management assistant. Maria will play a vital role in supporting our CEO with organizational and administrative tasks.

As of April 1, 2020, OncoOne has relocated its laboratory and office operations to the Vienna BioCenter. While our primary headquarters remains in Klosterneuburg, this move signifies an expansion of our presence within the vibrant scientific community at the Vienna BioCenter.